From the Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Department of Pathology, Harvard Medical School, Division of Women’s and Perinatal Pathology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston; InforMEDical Communications Inc, Carlisle, MA; Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, and Institute for Drug Development Cancer Therapy and Research Center, San Antonio, TX; Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California, Los Angeles, CA; Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA; Department of Obstetrics-Gynecology, University of Kentucky Medical Center, Lexington, KY; Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA; Hematology/Medical Oncology, The Cleveland Clinic Foundation and MetroHealth Medical Center, Cleveland, OH; Franklin Square Hospital Center, Baltimore, MD; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom; and Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Strathclyde, Glasgow, Scotland. The conference and proceedings publication were made possible by unrestricted educational grants from Aventis Pharmaceuticals and Ortho Biotech Products, L.P. CME Sponsorship was provided by InforMEDical Communications, Inc.
Address reprint requests to InforMEDical Communications Inc, 83 Acton St, Carlisle, MA 01741; email:[email protected].
